| Bioactivity | XR9051 is an orally active and specific modulator of P-glycoprotein-mediated multidrug resistance (MDR)[1]. |
| Invitro | XR9051 is able to reverse resistance to a variety of cytotoxic drugs, including doxorubicin, etoposide and vincristine, which are associated with classical MDR[1].XR9051 is highly active and gave at least a 15- to 20- fold decrease in the doxorubicin IC50, in the acquired resistance cell lines[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> XR9051 相关抗体: |
| In Vivo | XR9051 (20-40 mg/kg, ip) shows significant modulatory activity in mice bearing MDR human ovarian (2780AD and CH1/DOXr) and SCLC (H69/LX) xenografts[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
| CAS | 762219-35-2 |
| Formula | C39H38N4O5 |
| Molar Mass | 642.74 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. I L Dale , et al. Reversal of P-glycoprotein-mediated multidrug resistance by XR9051, a novel diketopiperazine derivative. Br J Cancer. 1998 Oct;78(7):885-92. [2]. P Mistry, et al. In vivo efficacy of XR9051, a potent modulator of P-glycoprotein mediated multidrug resistance. Br J Cancer. 1999 Apr;79(11-12):1672-8. |